Q-omics provides the consensus-scored MIR3165 profile across patient tissues and cancer cell-line models. MIR3165 expression is associated with patient survival in 6 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, MIR3165 is differentially expressed in 5, with the highest sampling consensus in BRCA. Additionally, MIR3165 RNA expression shows 8,365 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight MESO, BRCA, and LSCC as cancer lineages where MIR3165 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR3165 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR3165 survival associations across molecular data types. MIR3165 RNA expression shows survival associations in the most cancer types (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR3165 RNA expression–survival associations across cancer types. High MIR3165 expression shows unfavorable associations in MESO, ESCA, LIHC, PAAD, LUSC and CHOL. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify MESO as the clearest survival context for MIR3165 RNA expression.
This table summarizes MIR3165 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for MIR3165. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR3165 shows lower tumor expression in HNSC and higher tumor expression in BRCA, LUAD, COAD and THCA. The BRCA box plot shows higher MIR3165 RNA expression in tumor versus normal tissue (log2 FC = +0.382, t-test p = .003).
This table shows molecular features associated with MIR3165 in patient tissues and cancer cell lines. In patient samples, MIR3165 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
